Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers.

Master AM, Livingston M, Oleinick NL, Sen Gupta A.

Mol Pharm. 2012 Aug 6;9(8):2331-8. doi: 10.1021/mp300256e. Epub 2012 Jul 19.

2.

A cell-targeted photodynamic nanomedicine strategy for head and neck cancers.

Master A, Malamas A, Solanki R, Clausen DM, Eiseman JL, Sen Gupta A.

Mol Pharm. 2013 May 6;10(5):1988-97. doi: 10.1021/mp400007k. Epub 2013 Apr 24.

3.

EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies.

Master AM, Qi Y, Oleinick NL, Gupta AS.

Nanomedicine. 2012 Jul;8(5):655-64. doi: 10.1016/j.nano.2011.09.012. Epub 2011 Oct 22.

4.

Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies.

Master AM, Rodriguez ME, Kenney ME, Oleinick NL, Gupta AS.

J Pharm Sci. 2010 May;99(5):2386-98. doi: 10.1002/jps.22007.

PMID:
19967780
5.

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.

Whitacre CM, Feyes DK, Satoh T, Grossmann J, Mulvihill JW, Mukhtar H, Oleinick NL.

Clin Cancer Res. 2000 May;6(5):2021-7.

6.

π-π Stacking induced enhanced molecular solubilization, singlet oxygen production, and retention of a photosensitizer loaded in thermosensitive polymeric micelles.

Shi Y, Elkhabaz A, Yengej FA, van den Dikkenberg J, Hennink WE, van Nostrum CF.

Adv Healthc Mater. 2014 Dec;3(12):2023-31. doi: 10.1002/adhm.201400455. Epub 2014 Nov 11.

PMID:
25388924
7.

Immunosuppressive effects of silicon phthalocyanine photodynamic therapy.

Reddan JC, Anderson CY, Xu H, Hrabovsky S, Freye K, Fairchild R, Tubesing KA, Elmets CA.

Photochem Photobiol. 1999 Jul;70(1):72-7.

PMID:
10420845
8.

Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.

Baron ED, Malbasa CL, Santo-Domingo D, Fu P, Miller JD, Hanneman KK, Hsia AH, Oleinick NL, Colussi VC, Cooper KD.

Lasers Surg Med. 2010 Dec;42(10):728-35. doi: 10.1002/lsm.20984.

9.
10.

Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy.

Jiang Z, Shao J, Yang T, Wang J, Jia L.

J Pharm Biomed Anal. 2014 Jan;87:98-104. doi: 10.1016/j.jpba.2013.05.014. Epub 2013 May 18. Review.

PMID:
23746989
11.

Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.

Colussi VC, Feyes DK, Mulvihill JW, Li YS, Kenney ME, Elmets CA, Oleinick NL, Mukhtar H.

Photochem Photobiol. 1999 Feb;69(2):236-41.

PMID:
10048316
12.

Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer.

Wang D, Fei B, Halig LV, Qin X, Hu Z, Xu H, Wang YA, Chen Z, Kim S, Shin DM, Chen ZG.

ACS Nano. 2014 Jul 22;8(7):6620-32.

13.

Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles.

Zhao B, Yin JJ, Bilski PJ, Chignell CF, Roberts JE, He YY.

Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72. doi: 10.1016/j.taap.2009.08.010. Epub 2009 Aug 18.

14.

Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Soler DC, Ohtola J, Sugiyama H, Rodriguez ME, Han L, Oleinick NL, Lam M, Baron ED, Cooper KD, McCormick TS.

Photochem Photobiol Sci. 2016 Jun 8;15(6):822-31. doi: 10.1039/c6pp00058d. Epub 2016 May 10.

15.

Choline PET for monitoring early tumor response to photodynamic therapy.

Fei B, Wang H, Wu C, Chiu SM.

J Nucl Med. 2010 Jan;51(1):130-8. doi: 10.2967/jnumed.109.067579. Epub 2009 Dec 15.

16.

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

Miller JD, Baron ED, Scull H, Hsia A, Berlin JC, McCormick T, Colussi V, Kenney ME, Cooper KD, Oleinick NL.

Toxicol Appl Pharmacol. 2007 Nov 1;224(3):290-9. Epub 2007 Feb 15. Review.

17.

Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo.

Lu HL, Syu WJ, Nishiyama N, Kataoka K, Lai PS.

J Control Release. 2011 Nov 7;155(3):458-64. doi: 10.1016/j.jconrel.2011.06.005. Epub 2011 Jun 12.

PMID:
21689700
18.

Highly efficient photodynamic therapy colloidal system based on chloroaluminum phthalocyanine/pluronic micelles.

Py-Daniel KR, Namban JS, de Andrade LR, de Souza PE, Paterno LG, Azevedo RB, Soler MA.

Eur J Pharm Biopharm. 2016 Jun;103:23-31. doi: 10.1016/j.ejpb.2016.03.028. Epub 2016 Mar 24.

PMID:
27018329
19.

Monitoring Pc 4 photodynamic therapy in clinical trials of cutaneous T-cell lymphoma using noninvasive spectroscopy.

Lee TK, Baron ED, Foster TH.

J Biomed Opt. 2008 May-Jun;13(3):030507. doi: 10.1117/1.2939068.

20.

A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice.

Anderson CY, Freye K, Tubesing KA, Li YS, Kenney ME, Mukhtar H, Elmets CA.

Photochem Photobiol. 1998 Mar;67(3):332-6.

PMID:
9523532

Supplemental Content

Support Center